Plotted by close date where disclosed, otherwise announcement. Select any marker to jump to the deal entry.
Three patterns run through Guardant Health's acquisitions — what it looks for, how it pays, and how it folds in what it buys.
3 acquisitions — each with the deal value, financing structure, target revenue, and executive commentary where disclosed.
Guardant purchased all of the remaining shares of Guardant Health AMEA, Inc. held by SoftBank (SVF Excalibur (Cayman) Limited) and its affiliates, giving Guardant full control over its liquid-biopsy operations across the Asia, Middle East and Africa region. The AMEA entity, established in May 2018 as a joint venture between Guardant Health and the SoftBank Vision Fund, serves 41 countries across the region. The purchase price of $177.8 million was determined based on an independent third-party valuation, and the joint venture agreement was terminated concurrently with the closing. approximately $177.8 million.
By acquiring the remaining shares of Guardant Health AMEA, we can focus on creating a unified and centralized global organization that delivers on our promise to help conquer cancer and improve patient outcomes. We believe our blood-based tests can play a significant role in helping address the growing cancer burden in the region, and we look forward to continuing to support patients facing cancer diagnoses as we expand our operations in these markets.Helmy Eltoukhy — Chairman and co-CEO, Guardant Health
Guardant Health acquired MetaSight Diagnostics Ltd. in December 2025 for $93.0 million in total purchase consideration net of cash, structured as $59.0 million in upfront cash plus up to $90.0 million in contingent consideration. The Israel-based transaction added liquid-biopsy diagnostics technology for early cancer and disease detection to Guardant's portfolio. $93.0 million total purchase consideration net of cash ($59.0 million upfront cash plus up to $90.0 million contingent; $34.0 million contingent fair value at acquisition date).
In December 2025, the Company purchased all of the outstanding shares of MetaSight Diagnostics Ltd., or MetaSight, a health technology company. The transaction includes $59.0 million in upfront cash consideration paid at closing, plus up to $90.0 million in variable contingent consideration tied to future commercial performance and regulatory approvals of the MetaSight technology.Guardant Health FY25 10-K — Note 4 Acquisition
Bellwether Bio is a privately held company pioneering research into the epigenomic content of cell-free DNA to improve oncology patient care. Guardant Health acquired it to bolster its epigenomics capabilities for blood-based cancer detection.